Neurological, respiratory, musculoskeletal, cardiac and ocular side-effects of anti-PD-1 therapy.

@article{Zimmer2016NeurologicalRM,
  title={Neurological, respiratory, musculoskeletal, cardiac and ocular side-effects of anti-PD-1 therapy.},
  author={Lisa Zimmer and Simone Maria Goldinger and Lars Hofmann and Carmen Loquai and Selma Ugurel and Ioannis Thomas and Maria Isabel Schmidgen and Ralf Gutzmer and Jochen Utikal and Daniela Goeppner and Jessica C Hassel and Friedegund Meier and Julia K. Tietze and Andrea Forschner and Carsten Weishaupt and Martin Leverkus and Renate U Wahl and Ursula Dietrich and Claus Garbe and Michael C Kirchberger and Thomas Kurt Eigentler and Carola Berking and Anja Gesierich and Angela M. Krackhardt and Dirk Schadendorf and Gerold Schuler and Reinhard Dummer and Lucie Heinzerling},
  journal={European journal of cancer},
  year={2016},
  volume={60},
  pages={210-25}
}
BACKGROUND Anti-programmed cell death 1 (PD-1) antibodies represent an effective treatment option for metastatic melanoma and other cancer entities. They act via blockade of the PD-1 receptor, an inhibitor of the T-cell effector mechanisms that limit immune responses against tumours. As reported for ipilimumab, the anti-PD-1 antibodies pembrolizumab and nivolumab can induce immune-related adverse events (irAEs). These side-effects can involve skin, gastrointestinal tract, liver, the endocrine… CONTINUE READING